Revolution Medicines Inc
RVMDBuild a strategy around RVMD
Revolution Medicines Inc AI Insights
Informational only. Not investment advice.Snapshot
- R&D spend of 880M TTM is 85% of total opex (1.04B) - pure clinical-stage biotech with no revenue, burning 777M FCF annually[Research and Development TTM]
- Cash runway critical: 217M cash + 1.73B working capital vs 777M annual burn = ~2.5 years without dilution[Cash and Equivalents]
- Raised 772M via stock issuance TTM - equity dilution is primary funding mechanism with debt/equity at just 0.10[Issuance of Capital Stock TTM]
Watch Triggers
- Cash and Equivalents: Falls below 500M (including short-term investments) — Signals <18 months runway, forcing dilutive raise at potentially weak prices
- Research and Development TTM: Declines >20% quarter-over-quarter — May indicate pipeline prioritization or trial failures requiring cost cuts
- Total Revenue TTM: Any revenue recognition >10M — First revenue would signal partnership deal or early commercialization progress
Bull Case
Substantial R&D investment (880M TTM) positions for potential blockbuster approval. Working capital of 1.73B provides runway through key data readouts without immediate dilution.
Low leverage (0.10 debt/equity) preserves financial flexibility for partnerships or debt financing if trials succeed, avoiding forced dilution at weak prices.
Bear Case
Zero revenue with -961M net loss TTM. At current burn rate (-777M FCF), will require additional dilutive financing within 2-3 years regardless of trial outcomes.
ROE of -60.8% and ROIC of -56.4% TTM reflect capital destruction. Any clinical setback could trigger 50%+ equity value loss given zero revenue base.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage RVMD's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Binary clinical outcomes will drive 50%+ stock moves in either direction over next 12-18 months
- Zero revenue = 100% dependent on pipeline success
- 880M R&D spend indicates late-stage trials
- 2.5-year cash runway creates financing pressure
Valuation Context
Caveats
Public Strategies Rankings
See how Revolution Medicines Inc ranks across different investment strategies.
Leverage RVMD's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
RVMD Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$27.53B | — | ||
$27.3B | — | ||
0.00 | — | ||
$0 | — | ||
$-5.95 | — | ||
0% | — | ||
0% | — | ||
$-913.73M | — | ||
-58.1% | -28.7% | — | |
Beta 5Y (Monthly) | unknown | — |
RVMD Dividend History
RVMD Stock Splits
RVMD SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
02/25/26 | 12/31/25 | 10-K | |
11/05/25 | 09/30/25 | 10-Q | |
08/06/25 | 06/30/25 | 10-Q | |
05/07/25 | 03/31/25 | 10-Q | |
02/26/25 | 12/31/24 | Unknown | |
11/06/24 | 09/30/24 | 10-Q | |
08/07/24 | 06/30/24 | 10-Q | |
05/08/24 | 03/31/24 | 10-Q | |
02/26/24 | 12/31/23 | 10-K | |
11/06/23 | 09/30/23 | 10-Q | |
08/08/23 | 06/30/23 | 10-Q | |
05/08/23 | 03/31/23 | 10-Q | |
02/27/23 | 12/31/22 | 10-K | |
11/07/22 | 09/30/22 | 10-Q | |
08/09/22 | 06/30/22 | 10-Q | |
05/09/22 | 03/31/22 | 10-Q | |
02/28/22 | 12/31/21 | 10-K | |
11/10/21 | 09/30/21 | 10-Q | |
08/11/21 | 06/30/21 | 10-Q | |
05/10/21 | 03/31/21 | 10-Q | |
03/02/21 | 12/31/20 | 10-K | |
11/12/20 | 09/30/20 | 10-Q | |
08/10/20 | 06/30/20 | 10-Q | |
05/14/20 | 03/31/20 | 10-Q | |
03/30/20 | 12/31/19 | 10-K | |
02/13/20 | 09/30/19 | 424B4 | |
08/10/20 | 06/30/19 | 10-Q | |
05/14/20 | 03/31/19 | 10-Q | |
02/13/20 | 12/31/18 | 424B4 |